Nurse-led conversations to integrate palliative care for children with cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to implement a pediatric palliative care program by utilizing nurse-initiated conversations to facilitate early integration of palliative care in pediatric oncology. It is an open-label, randomized trial conducted at the Children's Hospital of Fudan University, where participants will be divided into an intervention group receiving the nurse-led program and a control group receiving routine palliative care. The intervention is designed to provide comprehensive support to children and their families during the critical period following an oncologic diagnosis or relapse. The program will last for six months and is based on a culturally adapted model of care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Children within eight weeks of initial oncologic diagnosis or within eight weeks of relapse/recurrent disease diagnosis
* Children speaking Chinese
* Children's family caregivers accompanying the child in the hospital (only one family member is eligible to take this role under current hospital policy)
* Children's family caregivers speaking Chinese
* Health care providers who are taking care of the eligible children, including but not limited to physicians, nurses, and social workers

Exclusion Criteria:

\- Children who, in the opinion of their physician, are not capable mentally or verbally of participating in the survey or interview

Where it's running

• Hemotology/Oncology Unit and Surgical Oncology Unit of Children's Hospital of Fudan University
  Shanghai, Minhang, China Recruiting

Study contacts

• Principal investigator: Xiaowen Zhai, MD — Children's Hospital of Fudan University
• Study coordinator: Lei Cheng, PhD
• Email: chenglei@fudan.edu.cn
• Phone: +8602164161784

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1

  This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07830199

• FAPI PET imaging with FAPI-RuiJ and FAPI-04 in solid tumors

  This study tests two FAP-targeted PET tracers (FAPI-RuiJ and FAPI-04) to see which better detects, stages, and monitors solid tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07776899

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

• SI-B036 in locally advanced or metastatic breast cancer and other solid tumors

  Scientists are testing SI-B036 to see if it is safe and tolerable in adults with advanced breast cancer or other solid tumors and to get early signals of whether it might help.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07753226

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.